DK0944397T3 - Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer - Google Patents

Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer

Info

Publication number
DK0944397T3
DK0944397T3 DK97905539T DK97905539T DK0944397T3 DK 0944397 T3 DK0944397 T3 DK 0944397T3 DK 97905539 T DK97905539 T DK 97905539T DK 97905539 T DK97905539 T DK 97905539T DK 0944397 T3 DK0944397 T3 DK 0944397T3
Authority
DK
Denmark
Prior art keywords
iscom
receptor molecules
antigenic substances
pct
matrix containing
Prior art date
Application number
DK97905539T
Other languages
Danish (da)
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bengtsson Karin Loevgren
Jill Ekstroem
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bengtsson Karin Loevgren, Jill Ekstroem, Bror Morein filed Critical Bengtsson Karin Loevgren
Application granted granted Critical
Publication of DK0944397T3 publication Critical patent/DK0944397T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK97905539T 1996-02-21 1997-02-20 Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer DK0944397T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600648A SE9600648D0 (sv) 1996-02-21 1996-02-21 Receptorbimdande enhet
PCT/SE1997/000287 WO1997030726A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances

Publications (1)

Publication Number Publication Date
DK0944397T3 true DK0944397T3 (da) 2004-06-01

Family

ID=20401482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905539T DK0944397T3 (da) 1996-02-21 1997-02-20 Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer

Country Status (12)

Country Link
US (1) US6027732A (pt)
EP (1) EP0944397B1 (pt)
AT (1) ATE258066T1 (pt)
AU (1) AU718443B2 (pt)
BR (1) BR9707638A (pt)
CA (1) CA2247103C (pt)
DE (1) DE69727314T2 (pt)
DK (1) DK0944397T3 (pt)
ES (1) ES2214608T3 (pt)
NZ (1) NZ331418A (pt)
SE (1) SE9600648D0 (pt)
WO (1) WO1997030726A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7776343B1 (en) * 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
IL162857A0 (en) * 2002-01-15 2005-11-20 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Oral vaccination
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.

Also Published As

Publication number Publication date
US6027732A (en) 2000-02-22
ES2214608T3 (es) 2004-09-16
SE9600648D0 (sv) 1996-02-21
CA2247103C (en) 2009-01-20
CA2247103A1 (en) 1997-08-28
AU2238397A (en) 1997-09-10
EP0944397B1 (en) 2004-01-21
ATE258066T1 (de) 2004-02-15
NZ331418A (en) 2000-03-27
DE69727314D1 (de) 2004-02-26
DE69727314T2 (de) 2004-11-18
BR9707638A (pt) 2000-01-04
AU718443B2 (en) 2000-04-13
EP0944397A1 (en) 1999-09-29
WO1997030726A1 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
DK0944397T3 (da) Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer
AU6253898A (en) Use of microparticles combined with submicron oil-in-water emulsions
HK1068933A1 (en) Feather-based padding product, preparation method and installation for implementing said method
AU6105398A (en) Antisun composition containing a solid elastomeric organopolysiloxane
AR087617A2 (es) Panel compuesto de arundo donax y metodo para elaborarlo
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ES2186273T3 (es) Dispositivo de molienda con doble paso de molido, aparato que utiliza el dispositivo y metodo que hace uso del dispositivo.
ATE252888T1 (de) Lipid haltige zusammenstellungen und deren verwendungen
AU6931301A (en) Method of providing an image on a substrate, and an ink for use therein
ATE389397T1 (de) Adjuvante zusammensetzungen
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
DE69120942D1 (de) Hilfsstoffzusammensetzungen in fester form, dispergieren in wässerigen medien
ES2187072T3 (es) Formulacion cosmetica estable a la luz que contiene butilmetoxi-dibenzoilmetano.
ES2113734T3 (es) Sistema de forjado para paredes y revestimientos en la construccion.
Hübscher et al. Bundesdeutsche Arbeitsgemeinschaft für Veränderliche Sterne eV (BAV): Beobachtungsergebnisse.
IL114141A0 (en) Method for preparing cloud stable extract
ATE145191T1 (de) Azofarbstoffe enthaltende molekularsiebe
ES2177321T3 (es) Composiciones cosmeticas que comprende un tensioactivo anionico de alquilpoliglicosido, una goma de galactomanano y sus utilizaciones.
UA29496C2 (uk) Ротор для перемішуючих пристроїв
Garcia Vargas et al. VizieR Online Data Catalog: Emission lines from giant HII regions (Garcia Vargas+, 1995)
AP2000001746A0 (en) Anti- first-pass effect compounds.
ITMI932171A1 (it) Procedimento per l'estrazione di colori naturali mediante bentonite
Kaluzny et al. VizieR Online Data Catalog: VI Photometry of variables in NGC 2243 (Kaluzny et al. 1996)